Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

Ancient DNA is telling us more and more about humans and environments long past. Could it also help rescue the future?

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Food delivery service Boons has positioned itself as a no-brainer for restaurants, charging just $1 per order on transactions ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...